$MAIA Biotechnology Inc.(MAIA)$ has positive progress and shared a new report yesterday and following is summary.
This is a prospectus supplement document from MAIA Biotechnology, Inc., related to the offering of up to $4,950,000 of common stock. It provides updated information supplementing the previous prospectus dated August 23, 2023. Key points include:
1. The offer of common stock is under Rule 415 of the Securities Act and involves certain limitations and provisions.
2. As of the date of the prospectus, the total public float of MAIA's common stock was approximately $34,903,391.
3. The highest closing price of the common stock prior to the date of the document was $2.11 per share.
4. A significant amount of common stock has been sold under General Instruction I.B.6 of Form S-3 during the prior 12-calendar-month period, resulting in a restriction that the company will not offer shares in a public offering that exceed one-third of their public float unless the public float remains below $75 million.
5. H.C. Wainwright & Co. is the agent for the offering.
6. The last reported sale price of MAIA's common stock on the NYSE American was $2.11 per share as of March 22, 2024.
7. The document stresses that the SEC has not approved or disapproved of the securities nor passed upon the accuracy of the prospectus supplement.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Great article, would you like to share it?
Perfect analysis
🤞